Leukemia, Myelomonocytic, Chronic: all 340 studies
Page 3 of 4. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.
- A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological MalignanciesTerminatedNCT04937166Phase 1
- FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesActive, not recruitingNCT04891757Phase 1
- Classical Monocyte Kinetics in Chronic Myelomonocytic LeukemiaCompletedNCT04775121Not applicable
- Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood DisordersActive, not recruitingNCT04761770Phase 2
- Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04734990Phase 1/2
- A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
- Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04655755Phase 1/2
- A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04609826Phase 1
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruitingNCT04603001Phase 1
- Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
- IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
- Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
- Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
- A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)WithdrawnNCT04264806Phase 2
- SNS-301 Monotherapy in High Risk MDS and CMMLWithdrawnNCT04217720Phase 2
- NTX-301 in MDS/AMLCompletedNCT04167917Phase 1
- Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeTerminatedNCT04160052Phase 1/2
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyStatus unknownNCT03873311Phase 4
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesCompletedNCT03746041Phase 1
- Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid MalignanciesActive, not recruitingNCT03682029Not applicable
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
- Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- Study of the Safety and Efficacy of APR-246 in Combination With AzacitidineCompletedNCT03588078Phase 1/2
- Ascorbic Acid Levels in MDS, AML, and CMML PatientsCompletedNCT03526666
- IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationCompletedNCT03515512Phase 1
- Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
- Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
- Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic SyndromesCompletedNCT03363399
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)Status unknownNCT03040401Phase 1/2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingNCT02935361Phase 1/2
- An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the NetherlandsCompletedNCT02891551
- A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic SyndromesTerminatedNCT02841540Phase 1
- Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
- Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT02546284Phase 1
- Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesActive, not recruitingNCT02530034Phase 1
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseCompletedNCT02197676Phase 2
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedNCT02190695Phase 2
- Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoLTerminatedNCT02147873Phase 2
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CompletedNCT02085798
- Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
- Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
- Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 1
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
- Registry on Hypomethylating Agents in Myeloid NeoplasmsCompletedNCT01595295
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Korean Post-marketing Surveillance for Sprycel®CompletedNCT01464047
- 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)CompletedNCT01404741Phase 2
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsCompletedNCT01398462Phase 1
- Lenalidomide in Patients With Chronic Myelomonocytic LeukemiaStatus unknownNCT01368757Phase 1/2
- Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic LeukemiaCompletedNCT01251627Phase 2
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
- Azacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01235117Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
- Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
- Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
- Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) FailureStatus unknownNCT01133886Phase 2
- Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01098084Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01048034Phase 2
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic LeukemiaTerminatedNCT01010256
- Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSCompletedNCT00744536Phase 2
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1